62146-62-7

Basic information

• Product Name: N-Cbz-1,4-diaminobutane
• Synonyms: N-Cbz-1,4-diaminobutane;benzyl 4-aminobutylcarbamate;(4-Aminobutyl)carbamic acid phenylmethyl ester;N-(Benzyloxycarbonyl)-1,4-butanediamine;benzyl N-(4-aminobutyl)carbamate
• CAS NO: 62146-62-7
• Molecular Formula: C₁₂H₁₈N₂O₂
• Molecular Weight: 222.28352
• Mol File: 62146-62-7.mol
• Article Data: 28

Chemical Properties

• Appearance: /
• Density: 1.088
• CAS DataBase Reference: N-Cbz-1,4-diaminobutane(CAS DataBase Reference)
• NIST Chemistry Reference: N-Cbz-1,4-diaminobutane(62146-62-7)
• EPA Substance Registry System: N-Cbz-1,4-diaminobutane(62146-62-7)

Safety Data

• Hazardous Substances Data: 62146-62-7(Hazardous Substances Data)

Usage

General Description

N-Cbz-1,4-diaminobutane, also known as Cbz-diaminobutane or 1,4-diaminobutane-2-carboxylic acid, is a chemical compound that is commonly used as a building block in organic synthesis. It is a diamine derivative with a carboxybenzyl (Cbz) protecting group attached to the nitrogen atoms. N-Cbz-1,4-diaminobutane is often utilized in the preparation of peptide-based drugs and as a reagent in the synthesis of other organic compounds. It is a white solid at room temperature and is typically handled and stored under inert atmosphere due to its reactivity towards air and moisture. N-Cbz-1,4-diaminobutane has a variety of applications in the pharmaceutical and chemical industries due to its versatility as a reagent in organic synthesis.

Upstream product

• 110-60-1 1,4-diaminobutane 
• 591-77-5 1-methyl-1,4-butanediamine 
• 501-53-1 benzyl chloroformate 
• 72553-33-4 methyl 2,2-diphenylbenzo[d][1,3]dioxole-4-carboxylate 
• 54888-41-4 2,3-<(diphenylmethylene)dioxy>benzoic acid 
• 2051-90-3 Dichlorodiphenylmethane 
• 4246-51-9 4,7,10-trioxa-1,13-diaminotridecane 
• 68076-36-8 1-amino-4-[(tert-butyloxycarbonyl)amino]butane 
• 174626-26-7 N-(benzyloxycarbonyl)-O-(methanesulfonyl)aminobutanol 
• 17996-13-3 benzyl 4-hydroxybutylcarbamate 
• 13139-17-8 N-(Benzyloxycarbonyloxy)succinimide 
• 123348-73-2 4-azido-N-benzyloxycarbonyl-1-butylamine 
• 28170-07-2 benzyl phenyl carbonate 
• 62146-59-2 Z-NH-(CH₂)4-NH-Boc 

Downstream Products

• 174623-85-9 3-(4-Benzyloxycarbonylamino-butylamino)-propionic acid tert-butyl ester 
• 419573-50-5 6-O-[2-N-[4-(benzyloxycarbonyl)butylamino]ethylamino]-3,2',6'-tris(N-benzyloxycarbonyl)-1-N-tert-butoxylcarbonyl-5,3',4'-tri-O-methoxymethylneamine 
• 62146-59-2 Z-NH-(CH₂)4-NH-Boc 
• 66647-12-9 [1-(4-benzyloxycarbonylamino-butylcarbamoyl)-3-methyl-butyl]-carbamic acid tert-butyl ester 
• 773072-10-9 N⁶-(benzyloxycarbonylaminobutyl)adenosine 
• 773072-11-0 N⁶-(4-benzyloxycarbonylaminobutyl)-5'-ethylamino-2',3'-isopropylidene-5'-oxo-5'-deoxyadenosine 
• 132502-56-8 N-4-benzyloxycarbonylaminobutyl-N,N'-di-tert-butoxycarbonylguanidine 
• 1228766-30-0 FmocGlu(OtBu)NH(CH₂)4NHZ 
• 117680-09-8 N⁴-Succinoyl-N¹,N⁸-bis(2,3-bis(benzyloxy)benzoyl)spermidine 
• 176245-99-1 trocCl 
• 176246-00-7 trocCl 
• 23441-10-3 N-Benzyloxycarbonyl-N^G-nitroagmatin 
• 123348-79-8 N-(benzyloxycarbonyl)-4-(dimethylamino)butylamine 
• 152754-92-2 [2-{[(E)-4-Benzyloxycarbonylamino-butylimino]-methyl}-4-(tert-butyl-dimethyl-silanyloxy)-butyl]-(3-tert-butoxycarbonylamino-propyl)-carbamic acid tert-butyl ester 

Relevant articles and documents

Bivalent Ligand Aiming Putative Mu Opioid Receptor and Chemokine Receptor CXCR4 Dimers in Opioid Enhanced HIV-1 Entry

A bivalent compound 1a featuring both a mu opioid receptor (MOR) and a CXCR4 antagonist pharmacophore (naltrexone and IT1t) was designed and synthesized. Further binding and functional studies demonstrated 1a acting as a MOR and a CXCR4 dual antagonist wi

Platform to Discover Protease-Activated Antibiotics and Application to Siderophore-Antibiotic Conjugates

Here we present a platform for discovery of protease-activated prodrugs and apply it to antibiotics that target Gram-negative bacteria. Because cleavable linkers for prodrugs had not been developed for bacterial proteases, we used substrate phage to discover substrates for proteases found in the bacterial periplasm. Rather than focusing on a single protease, we used a periplasmic extract of E. coli to find sequences with the greatest susceptibility to the endogenous mixture of periplasmic proteases. Using a fluorescence assay, candidate sequences were evaluated to identify substrates that release native amine-containing payloads. We next designed conjugates consisting of (1) an N-terminal siderophore to facilitate uptake, (2) a protease-cleavable linker, and (3) an amine-containing antibiotic. Using this strategy, we converted daptomycin - which by itself is active only against Gram-positive bacteria - into an antibiotic capable of targeting Gram-negative Acinetobacter species. We similarly demonstrated siderophore-facilitated delivery of oxazolidinone and macrolide antibiotics into a number of Gram-negative species. These results illustrate this platform's utility for development of protease-activated prodrugs, including Trojan horse antibiotics.

ANTIBACTERIAL SIDEROMYCINS

A compound, comprising: an Fe(III)-binding and/or Fe(III)-bound siderophore; one or more optional linker covalently bound to the siderophore; and daptomycin covalently bound to the linker, or, if no linker is present, then to the siderophore; or pharmaceu